Axovant Sciences Ltd (NASDAQ:AXON) reached a new 52-week low during trading on Monday . The company traded as low as $2.56 and last traded at $5.37, with a volume of 1411500 shares changing hands. The stock had previously closed at $5.24.

A number of research firms recently commented on AXON. Chardan Capital reiterated a “sell” rating and issued a $3.00 price objective on shares of Axovant Sciences in a report on Saturday, September 23rd. BidaskClub upgraded Axovant Sciences from a “strong sell” rating to a “sell” rating in a report on Saturday, September 23rd. ValuEngine downgraded Axovant Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Evercore ISI reiterated an “outperform” rating and issued a $9.00 price objective (down previously from $30.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Finally, Cowen reiterated an “outperform” rating and issued a $25.00 price objective (down previously from $30.00) on shares of Axovant Sciences in a report on Tuesday, September 26th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $14.18.

The firm has a market capitalization of $250.90 and a price-to-earnings ratio of -2.32. The company has a debt-to-equity ratio of 0.34, a quick ratio of 5.94 and a current ratio of 5.94.

Institutional investors have recently made changes to their positions in the business. Federated Investors Inc. PA bought a new stake in shares of Axovant Sciences in the second quarter worth about $1,408,000. Lord Abbett & CO. LLC bought a new stake in shares of Axovant Sciences in the second quarter worth about $696,000. Bank of New York Mellon Corp increased its holdings in shares of Axovant Sciences by 27.0% in the second quarter. Bank of New York Mellon Corp now owns 102,664 shares of the biotechnology company’s stock worth $2,380,000 after acquiring an additional 21,801 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Axovant Sciences in the second quarter worth about $47,854,000. Finally, OxFORD Asset Management LLP bought a new stake in shares of Axovant Sciences in the second quarter worth about $2,141,000. Institutional investors own 96.93% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Axovant Sciences (AXON) Reaches New 52-Week Low at $2.56” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2018/01/08/axovant-sciences-axon-reaches-new-52-week-low-at-2-56.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Stock Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related stocks with our FREE daily email newsletter.